Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer.
Sapu003 is an injectible from of Affinitor(R) (Everolimus), which is an FDA-approved drug for treating different types of advanced cancer including breast cancer, kidney cancer, and affiliated rare tumors.
When taken orally in pill form, only about 10% of the drug is absorbed by the body, limiting how effective it can be. With that in mind, using Sapu Nano’s novel Deciparticle(TM) technology, Sapu003 that’s injected intravenously opens 100% of the drug reach the bloodstream.
As a result, Sapu003 represents a new approach to administering an existing cancer drug. Delivering the drug intravenously lets researchers give it at full strength, which may make it more effective at reducing the size of tumors.
This first trial aims to see if this improved version of the drug gives breast cancer patients not only new hope, but also more long-term and enduring benefits.
Dr. Vuong Trieu, the CEO of Sapu Nano, stated, “We are extremely pleased to receive approval from HREC to proceed with human clinical trials,”. He also added that “Despite advances in treatment, a critical unmet need for next generation mTOR inhibitors remains. Current therapies often extend progression-free survival for less than one year and rarely deliver long-term disease control. This Phase 1 trial will allow us to determine the best dose for future studies, including a Phase 3 trial. (ibn.fm/dY3G0)”
Dr. Sud Agarwal, CEO of Ingenu, a contract research organization (“CRO”) in Australia, added that “the approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited. We are proud to support Sapu Nano in advancing this therapy, potentially giving breast cancer patients better outcomes and improved quality of life.”
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics is a biopharmaceutical company that develops therapeutics for cancer and other underserved diseases. The company has a portfolio of clinical-stage candidates and is focused on transforming outcomes for patients suffering from rare and/or difficult-to-treat conditions.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
A groundbreaking study led by a pair of researchers from Israel and involving research teams…
LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside…
ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management…
HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory…
Many times, a diagnosis of lung cancer comes late because the early symptoms may be…
One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM),…